Sysmex (OTCMKTS:SSMXY) Shares Down 7% – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares traded down 7% on Wednesday . The company traded as low as $11.70 and last traded at $11.70. 1,555 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 210,893 shares. The stock had previously closed at $12.5750.

Analyst Ratings Changes

Separately, Zacks Research cut shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Sysmex Trading Down 2.7%

The company has a market capitalization of $7.45 billion, a P/E ratio of 28.19 and a beta of 1.05. The business has a fifty day moving average price of $9.63 and a 200 day moving average price of $9.14. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.The business had revenue of $825.85 million during the quarter, compared to the consensus estimate of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. On average, analysts expect that Sysmex Corporation ADR will post 0.38 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.